A retrospective cohort study examined whether concurrent menopause hormone therapy modifies weight loss and cardiometabolic outcomes among postmenopausal women with overweight or obesity treated with...
On November 10, the U.S. Department of Health and Human Services announced that the FDA is initiating the removal of certain black box warnings from hormone replacement therapy products for menopause,...
A cross-sectional study of more than 2000 transgender, nonbinary, and gender-diverse adults found 44% had undergone gender-affirming surgery, 82% reported high satisfaction, and 94% faced barriers, most...
A randomized clinical trial found no significant difference in breast development between cyproterone acetate and spironolactone in transgender individuals undergoing feminizing hormone therapy. However,...
Recent updates in endocrinology reveal fezolinetant as a promising non-hormonal treatment for menopausal symptoms and tirzepatide’s impressive 93% risk reduction in progression from prediabetes to type 2...
Darolutamide monotherapy reduced prostate-specific antigen response in patients with hormone-sensitive prostate cancer while maintaining testosterone levels in a recent 24-week randomized study.
This week’s COVID-19 roundup coverage includes national trends in mortality due to alcohol use disorder during the pandemic, as well as the impact of hormone replacement therapy on COVID-19 mortality and...
The American College of Physicians has released a new guideline on the benefits and harms of testosterone treatment in men with age-related low testosterone.
In a new systematic review and meta-analysis, McMaster University researchers explored the impact of hormone therapy on muscle mass in postmenopausal women.
